Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03185741 · ClinicalTrials.gov registry record · NA
Regimen Education and Messaging in Diabetes (REMinD)
A NA study, sponsored by Northwestern University.
- Completed
- Registry status
- NA
- Development phase
- 767
- Enrollment target
NCT03185741 is a NA study that has completed, run by Northwestern University. The registered enrollment target is 767 participants.
The verdict
NCT03185741, a NA study, has completed, sponsored by Northwestern University.
- COMPLETED
- Registry status
- NA
- Development phase
- 767 participants
- Enrollment target
Study Summary
The investigators will leverage increasingly available technologies to impart a Universal Medication Schedule (UMS) in primary care to help patients living with diabetes safely use and adhere to complex drug regimens. The UMS standardizes the prescribing and dispensing of medicine by using health literacy principles and more explicit times to describe when to take medicine (morning, noon, evening, bedtime). This eliminates variability found in the way prescriptions are written by physicians and transcribed by pharmacists onto drug bottle labels. The proposed intervention will standardize prescribing within an electronic health record (EHR) so all medication orders include UMS prescription instructions ('sigs') and patients receive a medication information sheet with their after-visit summaries. Additionally, to help patients remember when to take prescribed medicines we will link unidirectional short message service (SMS) text reminders to the EHR, delivering medication reminders to patients around UMS intervals. 1. Test the effectiveness of the UMS, and UMS + SMS text reminder strategies compared to usual care. 2. Determine if the effects of these UMS strategies vary by patients' literacy skills and language. 3. Using mixed methods, evaluate the fidelity of the two strategies and explore patient, staff, physician, and health system factors influencing the interventions. 4. Assess the costs required to deliver either intervention from a health system perspective.
Interventions
- BEHAVIORAL SMS Text Messaging
- BEHAVIORAL UMS Strategy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 767 participants |
| Start Date | 2018-01-05 |
| Est. Completion | 2022-11-30 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03185741
The ClinicalTrials.gov registry entry for NCT03185741 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 767 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which SMS Text Messaging is the first listed.
NCT03185741 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03185741 about?
NCT03185741 is a clinical study titled "Regimen Education and Messaging in Diabetes (REMinD)". The investigators will leverage increasingly available technologies to impart a Universal Medication Schedule (UMS) in primary care to help patients living with diabetes safely use and adhere to complex drug regimens. The UMS standardizes the prescribing and dispensing of medicine by using health li...
What is the current status of trial NCT03185741?
This trial is currently completed. It is a NA study. The enrollment target is 767 participants. The study started on 2018-01-05. Estimated completion is 2022-11-30.
What interventions are being tested in trial NCT03185741?
The interventions under investigation include: SMS Text Messaging (BEHAVIORAL), UMS Strategy (BEHAVIORAL).
Who is sponsoring clinical trial NCT03185741?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.